Kencur for Digestive Health and the Beras Kencur Tradition

Jamu beras kencur, the sweet rice-and-rhizome tonic sold across Java, is where most people encounter kencur's reputation for digestive and restorative use. That tradition itself has never been tested directly. What has been tested, and what the main Kencur page does not cover, is a real cluster of gastric-protective animal studies, a genuine in-vitro finding against the ulcer-causing bacterium Helicobacter pylori, and — the newest and most unexpected thread — a family of previously undescribed compounds from kencur rhizome, discovered in 2023–2025, that stimulate the gut hormone GLP-1 and inhibit a carbohydrate-digesting enzyme. This page works through all of it, including why "more potent than acarbose in a test tube" is a much smaller claim than it sounds.

Table of Contents

  1. The Beras Kencur Tradition, and What "Digestive" Actually Meant
  2. Real Gastric-Protective Evidence: Two Rat Models
  3. Kencur Against Helicobacter pylori, in a Dish
  4. A New and Unexpected Finding: Diarylheptanoids and Blood Sugar
  5. Why Beating Acarbose in a Test Tube Is Not a Diabetes Treatment
  6. The Gut-Hormone Connection: TGR5 and Bile-Acid Signaling
  7. A 2025 Nanotechnology Finding: Extracellular Vesicles and Colitis
  8. An Older Finding Worth Naming: Cholesterol and Triglycerides
  9. What the Carminative Claim Itself Does Not Have
  10. Dosage and Safety Notes for the Digestive Tract
  11. Key Research Papers
  12. Connections

The Beras Kencur Tradition, and What "Digestive" Actually Meant

Jamu beras kencur — rice and kencur, ground together and blended with palm sugar, tamarind, and often ginger or lime — is one of the two or three best-known jamu preparations in Indonesia, sold from baskets by jamu gendong vendors and bottled for supermarkets. Traditionally it is taken as a general tonic: for appetite, tiredness, aching muscles after work, and as a strengthening drink for children and postpartum women. Alongside the drink, kencur decoctions and chewed rhizome are used across Java, Malaysia, and southern China for bloating, colic, poor appetite, and nausea, and the plant appears among the "carminative plants" screened in at least one older phytochemistry survey — a functional classification (something traditionally believed to relieve gas and settle the stomach) rather than a tested pharmacological claim.

None of that traditional digestive-tonic framing has been tested as such. No study has given people beras kencur and measured appetite, gas, bloating, or any digestive symptom against a placebo drink. What follows in this article is not a test of that tradition; it is a different and more specific body of evidence — laboratory and animal research on kencur's effect on the stomach lining, on a specific stomach bacterium, and, unexpectedly, on blood-sugar-related gut hormones — that happens to concentrate in the same organ system the tradition points to, without confirming the tradition's own claims.

Back to Table of Contents

Real Gastric-Protective Evidence: Two Rat Models

Two independent Chinese research groups, publishing within months of each other in 2023 and 2024, tested kencur rhizome preparations against chemically-induced gastric ulcers in rodents — a real, specific, and mechanistically detailed body of evidence that the main Kencur page does not mention at all.

Liu and colleagues (2024) gave mice an alcoholic rhizome extract for seven days before inducing gastric ulcers with concentrated ethanol, and measured the result by ulcer index (the percentage of stomach lining showing visible damage). Untreated ulcer controls averaged 17.63%; pretreatment with the extract at 100, 200, and 400 mg/kg reduced that to 13.42%, 11.65%, and 6.54% respectively — a clear, dose-dependent protective effect. The same study measured a wide panel of gastric mediators (myeloperoxidase, malondialdehyde, nitric oxide, prostaglandin E2, and several inflammatory cytokines and receptors) and found the extract normalized most of them toward control levels, with a proposed mechanism running through the TRPV1 pain/heat receptor pathway and gastric acid secretion. Notably, this study measured the extract's own kaempferol and luteolin content directly by HPLC (3,713 and 2,510 micrograms per gram respectively) and tested both compounds alongside the whole extract — a genuine strength, because it means any credit given to these two flavonoids is backed by confirming they were actually present in this specific material, not borrowed from a study of the isolated commodity compound in some other plant.

Liu and colleagues (2023, with a published correction in the same journal) took a formulation-science approach: rather than the crude extract, they prepared kencur's volatile oil as a self-microemulsifying solid dosage form — a delivery technology designed to solve the oil's poor water solubility and instability — and tested it in a separate rat gastric-ulcer model. The formulated oil increased protective mucosal factors (PGE2, TGF-alpha, EGF) and reduced inflammatory markers (IL-8, TNF-alpha) by suppressing the NF-κB/COX-2 pathway, the same signaling axis covered in detail on the pain and inflammation page. Seeing the identical pathway show up in stomach tissue and in paw/ear inflammation models, from unrelated research groups, is a modestly reassuring cross-check that the mechanism is real rather than an artifact of one lab's assay.

Both studies are rodent pretreatment models — the extract was given before the ulcer-inducing insult, which tests prevention rather than treatment of an existing ulcer, and neither has been replicated by an independent group or tested in a person. For peptic ulcer disease in a real patient, especially one on NSAIDs, with H. pylori infection, or with alarm symptoms (bleeding, weight loss, difficulty swallowing), proper diagnosis and treatment remain necessary; kencur is not a substitute.

Back to Table of Contents

Kencur Against Helicobacter pylori, in a Dish

Helicobacter pylori is the primary bacterial cause of gastritis, peptic ulcers, and a major risk factor for gastric cancer. Bhamarapravati and colleagues (2003) tested extracts of 20 Thai spice and food plants, used traditionally for gastrointestinal complaints, against 18 clinical and reference strains of H. pylori. Kencur rhizome extract inhibited growth with a minimum inhibitory concentration (MIC) of 25.0 micrograms per milliliter — a real, quantified result, tied for second-strongest in the panel behind nutmeg aril (12.5 µg/mL), and notably stronger than several other extracts tested at 50–100 µg/mL.

The context the researchers offered is worth repeating honestly: Thailand has a high prevalence of H. pylori infection but a lower-than-expected rate of gastric cancer compared with other countries with similarly high infection rates, and the authors speculated that dietary use of plants like this one might partly explain the discrepancy. That is a hypothesis about population-level dietary patterns, built on an epidemiological curiosity, not a demonstrated causal chain from kitchen use of kencur to reduced cancer risk in an individual. What is solid is the in-vitro MIC number itself: real, specific, and measured against clinical bacterial isolates, not merely a lab reference strain.

No study has tested whether eating kencur, or any achievable culinary or supplement dose, delivers anything close to 25 µg/mL of active compound to the stomach lining in a living person, so this result should be read as "kencur extract has real, measurable anti-H. pylori activity in a laboratory dish" rather than "eating kencur treats or prevents H. pylori infection." A confirmed H. pylori infection needs the standard antibiotic eradication regimen a clinician prescribes; kencur is not an alternative to that treatment.

Back to Table of Contents

A New and Unexpected Finding: Diarylheptanoids and Blood Sugar

The single most surprising thread in kencur's recent literature has nothing to do with EPMC, the compound that dominates every other section of this Benefits set. Between 2023 and 2025, a research group centered at the Kunming Institute of Botany (Chinese Academy of Sciences) published a sequence of three papers isolating an entirely different class of compounds — diarylheptanoids, a structural family better known from ginger and turmeric relatives — from kencur rhizome, and testing them specifically for antidiabetic activity.

GLP-1 (glucagon-like peptide-1) is the same gut hormone targeted by the class of drugs that includes semaglutide and liraglutide, which is precisely why a plant-derived GLP-1 secretagogue is scientifically interesting. It is equally why the next section exists: interesting enzyme chemistry and drug-adjacent hormone biology are not, on their own, a diabetes treatment.

Back to Table of Contents

Why Beating Acarbose in a Test Tube Is Not a Diabetes Treatment

It is worth being precise about what "more potent than acarbose" actually means in the Li 2025 finding above, because the comparison is easy to overstate. The IC50 values being compared — 35.1 µM for kaemgalanganol B versus 363.0 µM for acarbose — describe how much of each compound is needed to inhibit the enzyme by half in a test tube, with purified enzyme, no digestive system, no absorption, no metabolism, and no other physiology involved. That is a real and useful piece of chemistry — it tells you the molecule has a genuinely strong binding interaction with the enzyme's active site — but it says nothing about what happens when the compound is swallowed by a person with type 2 diabetes.

Acarbose itself is a useful reference point precisely because its own ceiling, established across decades of real clinical trials, is known and modest: as a class, alpha-glucosidase inhibitors typically lower HbA1c (the standard 3-month blood-sugar control marker) by roughly 0.5–0.8 percentage points, meaningful but well below what metformin, GLP-1 agonists, or insulin achieve, and acarbose is generally used as an add-on therapy rather than a first-line treatment for exactly that reason. A newly discovered plant compound that out-competes acarbose for the same enzyme's active site in a dish has, at absolute best, a ceiling in that same modest range for this particular mechanism — and that is before accounting for the fact that kaemgalanganol B has never been tested in an animal model of diabetes, let alone a person, so its actual oral bioavailability, its behavior once metabolized, and its real effect on blood sugar in a living organism are all completely unknown. "Beats a real drug's enzyme-binding number in a test tube" is a genuinely exciting first step in early drug discovery; it is not a reason to expect kencur, in any current form, to meaningfully affect a person's blood sugar.

A separate 2025 study lends some very indirect support to the idea that this activity is not purely an artifact of isolated compounds: Windarsih and colleagues tested crude extracts (not isolated diarylheptanoids) of five Zingiberaceae rhizomes, including kencur, for alpha-glucosidase inhibition, and found kencur extract inhibited the enzyme by 86.13% at the concentration tested — the second-highest of the five species, behind turmeric (Curcuma domestica, 98.42%) and ahead of greater galangal, ginger, and Javanese turmeric. This is whole-extract activity, not proof that the specific diarylheptanoid compounds above are responsible, but it is at least consistent with kencur rhizome as a whole carrying real alpha-glucosidase-inhibiting activity rather than the effect being confined to a handful of exotic isolated molecules.

Back to Table of Contents

The Gut-Hormone Connection: TGR5 and Bile-Acid Signaling

An earlier, independent line of evidence connects to the same gut-hormone territory from a different angle. Ladurner and colleagues (2017), screening nineteen plant extracts from a traditional Tibetan formula for activity against TGR5 — a bile-acid-sensing receptor in the intestine that, when activated, triggers secretion of both GLP-1 and peptide YY (PYY, a separate appetite-regulating gut hormone) — found that kencur extract significantly activated the receptor, alongside extracts of clove and allspice. Follow-up chemical analysis attributed clove's and allspice's activity specifically to a class of triterpene acids (oleanolic, ursolic, corosolic, and maslinic acid); kencur's active constituent for this particular effect was not isolated in the same study, so it is a real, confirmed whole-extract effect on a legitimate metabolic drug target, without yet knowing precisely which of kencur's many compounds is responsible.

Taken together with the diarylheptanoid GLP-1 findings above, there are now two independent mechanistic routes — one confirmed as running through TGR5, one confirmed as TGR5-independent and running through PKA-CREB signaling instead — by which kencur constituents appear capable of triggering gut-hormone secretion in cell culture. Two independent mechanisms converging on the same downstream hormone is a more interesting and more credible signal than either alone, though it remains, again, cell-culture pharmacology rather than evidence of an effect in a whole organism.

Back to Table of Contents

A 2025 Nanotechnology Finding: Extracellular Vesicles and Colitis

The newest and most technologically unusual finding in this collection: Lin and colleagues (December 2025) isolated plant-derived extracellular vesicles — tiny (roughly 134 nanometer) lipid-membrane particles that plant cells, like animal cells, naturally release, carrying a cargo of lipids, proteins, and other bioactive molecules — from kencur rhizome, and tested them in a mouse model of ulcerative colitis induced by dextran sulfate sodium (DSS).

Given orally, the vesicles accumulated specifically in the colorectal region within six hours — a targeted delivery result driven simply by where in the gut an orally-dosed particle of this size and composition ends up, rather than any added targeting technology — and measurably reduced disease severity: less body-weight loss, lower disease-activity scores, and less of the spleen enlargement and colon shortening that mark active colitis in this model. The proposed mechanisms included repairing the intestinal barrier, reducing oxidative stress and colonic inflammation, favorably shifting gut microbiota composition, and reducing the polarization of macrophages toward their pro-inflammatory state.

This is early, single-study, animal-only research into a genuinely novel drug-delivery concept (using a food plant's own natural nanoparticles as an oral therapeutic vehicle) rather than anything resembling a traditional herbal claim, and it should be read that way: a promising direction for future pharmaceutical research, not a reason for a person with ulcerative colitis to eat more kencur. Inflammatory bowel disease requires ongoing specialist management, and nothing here changes that.

Back to Table of Contents

An Older Finding Worth Naming: Cholesterol and Triglycerides

One older study rounds out the metabolic picture. Achuthan and Padikkala (1997), working from the Ayurvedic use of both greater galangal and kencur rhizome for "inflammatory diseases, diabetes mellitus and obesity," gave rats a high-cholesterol diet alongside daily ethanolic extract (20 mg/day) of either plant for four weeks. Both extracts lowered serum and tissue total cholesterol, triglycerides, and phospholipids, and raised HDL ("good") cholesterol, in each case relative to untreated high-cholesterol controls.

This is a small, nearly thirty-year-old study without modern reporting standards (no stated sample size per group in the available abstract, no blinding described), and it has not been repeated. It is included because it is genuinely about kencur rhizome specifically, rather than a borrowed isolated compound, and because a rat study finding improved lipid markers is at least directionally consistent with the broader (if equally untested in humans) traditional Ayurvedic framing of kencur as useful in metabolic and inflammatory conditions. It should not be read as more than that single, old, unreplicated data point.

Back to Table of Contents

What the Carminative Claim Itself Does Not Have

Stepping back: everything in this article so far is real evidence about kencur's effect on specific, measurable things — ulcer index, bacterial growth, enzyme inhibition, hormone secretion, lipid panels. None of it is a test of the actual traditional claim that started this page: that jamu beras kencur, or kencur eaten as a carminative, relieves bloating, settles an upset stomach, or stimulates appetite in a person who drinks or eats it. That is an absence of evidence, not evidence of absence — nobody has run the relevant human trial, positive or negative — and it is worth stating as its own finding rather than letting the gastric-ulcer and diarylheptanoid research above stand in for it by association. A rat's stomach lining healing faster after a chemical burn, or an isolated enzyme binding a rhizome compound in a dish, is simply a different question from whether a bowl of sweet rice-and-kencur tonic reduces a person's bloating after a meal.

Back to Table of Contents

Dosage and Safety Notes for the Digestive Tract

No dose of kencur has been established for any digestive indication in a human trial, so the guidance here is necessarily about customary use rather than evidence-based dosing. Traditional jamu beras kencur servings use roughly 10–20 g of fresh rhizome, and commercial bottled versions are often heavily sweetened with palm sugar — worth checking on the label if blood sugar is a personal concern, which sits a little awkwardly alongside the diarylheptanoid research above: a sugar-laden commercial tonic is not how any of that emerging antidiabetic chemistry was tested, and drinking one does not deliver a meaningful dose of the isolated compounds described above. For anyone with diagnosed gastritis, peptic ulcer disease, H. pylori infection, inflammatory bowel disease, or diabetes, kencur in food amounts is reasonable to continue enjoying; it is not a treatment for any of those conditions, and the acute and subacute rat toxicology summarized on the pain and inflammation page found no gastrointestinal organ toxicity at the doses tested, which is reassuring for food-level use without being a substitute for actual safety data in people with digestive disease.

Back to Table of Contents

Key Research Papers

  1. Liu H, Chen Y, Hu Y, et al. Protective effects of an alcoholic extract of Kaempferia galanga L. rhizome on ethanol-induced gastric ulcer in mice. Journal of Ethnopharmacology, 2024;325:117845. — PubMed
  2. Liu D, Liu R, Zhuang Z, et al. Preparation of self-microemulsion solids of Kaempferia galanga (L.) volatile oil and its effect on rats with gastric ulcer. AAPS PharmSciTech, 2023;24(8):243 (correction 2023;24(8):257). — PubMed
  3. Bhamarapravati S, Pendland SL, Mahady GB. Extracts of spice and food plants from Thai traditional medicine inhibit the growth of the human carcinogen Helicobacter pylori. In Vivo, 2003;17(6):541–544. — PubMed
  4. Wang T, Wu SL, Liu P, et al. Diarylheptanoids with hypoglycemic potency from the rhizomes of Kaempferia galanga. Fitoterapia, 2023;167:105502. — PubMed
  5. Li XY, Wang T, Wu SL, Huang XY, Ma YB, Geng CA. New C-linked diarylheptanoid dimers as potential alpha-glucosidase inhibitors. International Journal of Biological Macromolecules, 2025;295:139496. — PubMed
  6. Wu SL, Wang T, Li XY, Gongpan P, Huang XY, Ma YB, Geng CA. Antidiabetic constituents of Kaempferiae rhizoma: previously undescribed O-linked diarylheptanoid dimers promoting GLP-1 secretion via PKA-CREB pathway. Phytochemistry, 2025;236:114496. — PubMed
  7. Windarsih A, Indrianingsih AW, Suryani R, et al. Evaluation of the antioxidant, antidiabetic, and antibacterial activity of Curcuma domestica, Zingiber officinale, Alpinia galanga, Curcuma xanthorrhiza, and Kaempferia galanga. Chemistry & Biodiversity, 2025;22(10):e00645. — PubMed
  8. Ladurner A, Zehl M, Grienke U, et al. Allspice and clove as source of triterpene acids activating the G protein-coupled bile acid receptor TGR5 (includes Kaempferia galanga). Frontiers in Pharmacology, 2017;8:468. — PubMed
  9. Lin L, Zhou X, Peng B, et al. Extracellular vesicles derived from Kaempferia galanga L. show promise for targeted oral therapy in the treatment of ulcerative colitis. Journal of Nanobiotechnology, 2025;24(1):26. — PubMed
  10. Achuthan CR, Padikkala J. Hypolipidemic effect of Alpinia galanga (Rasna) and Kaempferia galanga (Kachoori). Indian Journal of Clinical Biochemistry, 1997;12(1):55–58. — PubMed
  11. Kanjanapothi D, Panthong A, Lertprasertsuke N, et al. Toxicity of crude rhizome extract of Kaempferia galanga L. (Proh Hom). Journal of Ethnopharmacology, 2004;90(2–3):359–365. — PubMed

Back to Table of Contents

Connections

Back to Table of Contents